Pharmacotherapy of COVID-19: in vitro and in vivo application of remdesivir

Mariana de Almeida Rosa Rezende, Alice Ferreira Cordeiro, Andrey Paradela de Sousa, Isadora Valério da Silveira

Abstract


The coronavirus (SARS-CoV-2) is a pathogen that causes severe acute respiratory syndrome in humans (COVID-19). Its outbreak has engulfed the world suddenly, leading to a global pandemic crisis. This review article was designed to evaluate the existing evidence and experience related to an already-approved pharmacologic agent called remdesivir. PubMed, Scopus, Web of Science, and SCIELO databases were used to search for word-combinations, such as “COVID-19 AND Remdesivir” or “SARS-CoV-2 AND
Remdesivir”. Four reviewers independently searched results and abstracted data from selected studies up to March 21. Remdesivir has been shown to inhibit SARS-CoV-2, in vitro and in vivo, with therapeutic potential in treating patients hospitalized with COVID-19. However, it has been associated with the
development of adverse effects.


Keywords


pharmacotherapy; COVID-19; antiviral.



DOI: http://dx.doi.org/10.14450/2318-9312.v34.e1.a2022.pp45-57

Refbacks

  • There are currently no refbacks.


Copyright (c) 2022 Mariana de Almeida Rosa Rezende, Alice Ferreira Cordeiro, Andrey Paradela de Sousa, Isadora Valério da Silveira

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Infarma - Ciências Farmacêuticas

ISSN - 2318-9312 (Versão eletrônica)

ISSN - 0104-0219 (Versão impressa)

Conselho Federal de Farmácia - CFF

SHIS QI 15 Lote "L" - Lago Sul - Brasília - DF

CEP: 71635-615 - Fone: (61)3878-8751

e-mail:infarma@cff.org.br

Diretoria

Walter da Silva Jorge João, Presidente do Conselho Federal de Farmácia

Lenira da Silva Costa, Vice-Presidente do Conselho Federal de Farmácia

João Samuel de Morais Meira, Tesoureiro do Conselho Federal de Farmácia

Luiz Gustavo de Freitas Pires, Secretário-Geral do Conselho Federal de Farmácia